RSV 199
Alternative Names: RSV-199Latest Information Update: 31 Mar 2025
At a glance
- Originator IDBiologics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metapneumovirus infections; Respiratory syncytial virus infections
Most Recent Events
- 08 Mar 2025 Preclinical trials in Metapneumovirus infections (Prevention) in USA (Parenteral) prior to March 2025 (IDBiologics pipeline, March 2025)
- 08 Mar 2025 Preclinical trials in Respiratory syncytial virus infections (Prevention) in USA (Parenteral) prior to March 2025 (IDBiologics pipeline, March 2025)
- 08 May 2020 Vanderbilt University Medical Center and IDBiologics agree to develop monoclonal antibody medicines for COVID-2019 infections, Influenza virus infections, Respiratory syncytial virus infections, Zika virus infection